
Kevin Smith
Journalist
Bristol Myers Squibb's Zenbexus reduces risk of progression in multiple myeloma by 51%
The company has unveiled positive results from a Phase III study. The trial evaluated the efficacy of Zenbexus combined with Daratumumab and Dexamethasone (the ZDd triplet) in 800 patients with relapsed or refractory multiple myeloma (RRMM), at first relapse.
October 08, 2026 at 10:13 am
Will AI spell the end of Booking?
That's at least what investors seem to think, penalizing the hotel-booking platform and bringing its market capitalization down to a multiple of its earnings that it had not seen since the peak of pandemic-related panic.
October 06, 2026 at 05:42 am
Discover our authors
- Stock Market
- Our authors
- Kevin Smith



















